Biomarker Analysis Services for Cancer Pain
Ace Therapeutics offers specialized biomarker analysis services tailored for cancer pain research and drug discovery. Our comprehensive biomarker panel is designed to advance understanding of the molecular and cellular mechanisms underlying cancer pain, enabling the identification and characterization of novel therapeutic targets. All services are exclusively focused on supporting drug discovery and preclinical development stages; we do not provide clinical diagnostic services.
Effective therapeutic intervention begins with the precise identification of relevant biomarkers. At Ace Therapeutics, our biomarker discovery services form the foundation of preclinical drug development by systematically identifying, screening, and validating molecular markers associated with cancer pain. Through high-throughput screening and robust validation processes, we ensure that only the most relevant and reliable candidates are prioritized for further study, supporting the rational development of new therapeutic strategies.
Multi Omics: Our multi-omics approach integrates cutting-edge technologies, including genomics, transcriptomics, proteomics, and metabolomics, to provide a comprehensive view of biological systems relevant to cancer pain. By analyzing DNA, RNA, protein, and metabolite profiles, we uncover key molecular signatures and pathways implicated in pain signaling, inflammation, drug response, and cellular stress. This holistic strategy enables the identification of novel biomarkers and elucidates complex disease mechanisms, particularly those involving drug transporters, inflammatory mediators, and opioid signaling pathways.
Candidate Validation: Candidate biomarker validation at Ace Therapeutics involves rigorous strategies to confirm their association with cancer pain pathophysiology. Preliminary screening processes include assessment of expression patterns, functional relevance, and correlation with disease models. Promising candidates are prioritized based on biological plausibility, reproducibility, and their potential to inform therapeutic development. Criteria for advancement include robust association with pain mechanisms, feasibility of assay development, and potential translational value.
Diverse Technological Platforms: We offer custom assay development capabilities across a wide range of technological platforms, ensuring flexibility and adaptability to project-specific requirements. Our laboratory infrastructure supports the integration of immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and advanced histopathology and imaging, enabling precise and quantitative measurement of diverse biomarker types.
Immunoassays: We develop and employ ELISA, chemiluminescent, and multiplex immunoassays for sensitive and specific detection of protein biomarkers, including cytokines and receptor proteins.
Mass Spectrometry: Our LC-MS/MS platforms provide high-resolution, quantitative analysis of peptides, proteins, and metabolites, supporting targeted and untargeted biomarker discovery.
Flow Cytometry: Flow cytometry enables multiparametric analysis of cell surface and intracellular markers, facilitating the study of immune cell phenotypes and receptor expression relevant to cancer pain.
Molecular Diagnostics: We utilize PCR, qPCR, and next-generation sequencing for the detection and quantification of genetic and transcriptomic biomarkers, including gene variants and expression levels.
Histopathology And Imaging: Advanced histopathology and imaging techniques, including immunohistochemistry and digital image analysis, are applied for spatial localization and quantification of biomarkers within tissue samples.
Rigorous Method Validation: All assay methods undergo rigorous validation according to established guidelines, assessing performance characteristics such as sensitivity, specificity, accuracy, precision, and reproducibility. Quality control measures are implemented throughout the process to ensure data integrity and reliability, supporting robust preclinical biomarker research.
Our quantitative analysis capabilities enable precise measurement of biomarker concentrations across diverse sample types. We employ validated calibration standards, internal controls, and advanced data analysis pipelines to ensure the accuracy and reproducibility of results, facilitating the comparison of biomarker levels across experimental groups and time points.
Sample Analysis: Ace Therapeutics handles a variety of preclinical sample types, including tissue homogenates, plasma, serum, and cell lysates. Our standardized protocols encompass sample preparation, storage, and processing, with stringent quality measures to minimize variability and ensure the integrity of analytical results.
High Throughput Capabilities: High-throughput, multiplexed analytical platforms allow for the simultaneous measurement of multiple biomarkers from limited sample volumes, increasing efficiency and conserving valuable specimens. Automated workflows and data management systems further enhance throughput, supporting large-scale biomarker studies in preclinical research.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| ATP binding cassette subfamily B member 1 (ABCB1) | ATP binding cassette subfamily B member 1 (ABCB1), also known as P-glycoprotein or MDR1, is a transmembrane protein that functions as an ATP-dependent efflux pump. It is primarily involved in transporting a wide range of substrates, including xenobiotics, toxins, and drugs, out of cells. ABCB1 is highly expressed in tissues with barrier functions, such as the intestinal epithelium, blood-brain barrier, liver, and kidney, where it limits the absorption and promotes the excretion of various compounds. By mediating the efflux of drugs and other substances, ABCB1 plays a critical role in pharmacokinetics and the protection of tissues from potentially harmful agents. | ABCB1 expression and activity have been utilized as biomarkers in the context of drug resistance, particularly in oncology. Elevated levels of ABCB1 are associated with multidrug resistance in several types of cancer, as the protein can actively export chemotherapeutic agents from cancer cells, reducing their intracellular concentrations and efficacy. Measurement of ABCB1 expression or function in tumor samples or circulating cells can provide information relevant to predicting response to certain chemotherapeutic regimens. Additionally, ABCB1 status has been investigated in relation to drug pharmacokinetics and toxicity in non-oncologic settings. |
| NFE2 like bZIP transcription factor 2 (NFE2L2) | NFE2 like bZIP transcription factor 2 (NFE2L2), also known as NRF2, is a transcription factor that plays a central role in cellular defense against oxidative and electrophilic stress. Under basal conditions, NFE2L2 is sequestered in the cytoplasm by its inhibitor KEAP1 and targeted for proteasomal degradation. Upon exposure to oxidative stress or electrophilic agents, NFE2L2 dissociates from KEAP1, translocates to the nucleus, and binds to antioxidant response elements (ARE) in the promoter regions of target genes. This activation leads to the transcription of a variety of cytoprotective genes involved in antioxidant defense, detoxification, and maintenance of cellular redox homeostasis. NFE2L2-regulated genes include those encoding glutathione biosynthesis enzymes, NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), and various drug-metabolizing enzymes. | NFE2L2 expression levels, mutations, and pathway activation status have been investigated as biomarkers in several contexts. In oncology, aberrant activation of the NFE2L2 pathway, often due to mutations in NFE2L2 or KEAP1, has been associated with chemoresistance and poor prognosis in certain cancer types, including lung and liver cancers. In addition, NFE2L2 activity has been studied as a biomarker of oxidative stress and cellular response to environmental toxins or pharmacological agents. Measurement of NFE2L2 or its downstream target gene expression is utilized in research and clinical studies to assess cellular redox status and the activity of antioxidant defense mechanisms. |
| opioid receptor mu 1 (OPRM1) | Opioid receptor mu 1 (OPRM1) encodes the mu-opioid receptor, a G protein-coupled receptor that is primarily expressed in the central and peripheral nervous systems. This receptor binds endogenous opioid peptides such as beta-endorphin, as well as exogenous opioids including morphine and other analgesic drugs. Activation of the mu-opioid receptor leads to inhibition of adenylate cyclase activity, reduced neuronal excitability, and decreased neurotransmitter release, resulting in analgesic, sedative, and euphoric effects. OPRM1 is involved in the modulation of pain perception, reward pathways, and various physiological responses to opioids. | OPRM1 has been studied as a biomarker in the context of opioid response, dependence, and addiction. Genetic variants, particularly the A118G (rs1799971) polymorphism, have been associated with inter-individual variability in opioid efficacy, adverse effects, and susceptibility to opioid use disorder. Assessment of OPRM1 genotype has been explored in research settings for its potential to inform personalized approaches to pain management and to evaluate risk factors for opioid-related outcomes. |
| opioid related nociceptin receptor 1 (OPRL1) | Opioid related nociceptin receptor 1 (OPRL1), also known as the nociceptin/orphanin FQ receptor (NOP receptor), is a G-protein coupled receptor that binds the endogenous neuropeptide nociceptin (orphanin FQ). OPRL1 is structurally related to classical opioid receptors (mu, delta, kappa) but exhibits distinct pharmacological properties. Activation of OPRL1 modulates various physiological processes, including pain transmission, stress response, reward pathways, and mood regulation. The receptor is widely expressed in the central nervous system and peripheral tissues, where it influences neuronal excitability and neurotransmitter release. | OPRL1 has been investigated as a biomarker in several contexts, particularly in relation to pain sensitivity, substance use disorders, and neuropsychiatric conditions. Altered expression or genetic variation in OPRL1 has been associated with differences in pain perception, opioid response, and vulnerability to addiction. In research settings, OPRL1 may be measured to explore its role in disease mechanisms or to assess potential associations with clinical phenotypes, especially those involving nociceptive processing or addictive behaviors. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF), also known as TNF-alpha, is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as other immune cells such as T lymphocytes and natural killer cells. TNF plays a central role in mediating inflammation and immune responses. It exerts its effects by binding to TNF receptors (TNFR1 and TNFR2) on target cells, triggering intracellular signaling cascades that can lead to cell survival, apoptosis, or necrosis, depending on the cellular context. TNF is involved in the regulation of immune cell proliferation, differentiation, and activation, and it contributes to the pathogenesis of various inflammatory and autoimmune diseases. Additionally, TNF is implicated in the acute phase reaction, fever induction, and the recruitment of immune cells to sites of infection or injury. | TNF has been measured in biological fluids, such as serum or plasma, as an indicator of systemic inflammation. Elevated TNF levels have been observed in a range of inflammatory and autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and sepsis. Its concentration may be used to assess disease activity, monitor response to anti-TNF therapies, or provide prognostic information in certain clinical settings. TNF is also studied as a biomarker in cancer, infectious diseases, and metabolic disorders, where its levels may reflect underlying immune activation or disease progression. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services are designed to support exploratory and preclinical investigations into the molecular mechanisms of cancer pain. We offer a broad range of analytical capabilities for the identification, characterization, and quantification of research biomarkers. Please note that all biomarkers discussed are research targets only; we do not claim any as validated or mandatory for cancer pain studies. Our work is strictly focused on preclinical research stages, maintaining scientific objectivity and rigor throughout the process.
We invite you to connect with Ace Therapeutics to discuss collaborative opportunities in exploratory biomarker research for cancer pain. Our team is committed to scientific collaboration and knowledge exchange, supporting the advancement of preclinical discovery through objective and rigorous investigation.
Make Order
Experimental Scheme
Implementation
Conclusion
